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Background: Depression is associated with poor insulin sensitivity. We evaluated the long-term
effects of a cognitive behavioral therapy (CBT) program for prevention of depression on insulin
sensitivity in adolescents at risk for type 2 diabetes (T2D) with depressive symptoms.
Methods:One-hundrednineteenadolescent femaleswithoverweight/obesity, T2D familyhistory,
and mild-to-moderate depressive symptoms were randomized to a 6-week CBT group (n = 61)
or 6-week health education (HE) control group (n = 58). At baseline, posttreatment, and 1 year,
depressive symptoms were assessed, and whole body insulin sensitivity (WBISI) was estimated
fromoral glucose tolerance tests. Dual energy X-ray absorptiometry assessed fatmass at baseline
and 1 year. Primary outcomes were 1-year changes in depression and insulin sensitivity, adjusting
for adiposity and other relevant covariates. Secondary outcomeswere fasting and 2-hr insulin and
glucose.We also evaluated themoderating effect of baseline depressive symptom severity.
Results:Depressive symptoms decreased in both groups (P < .001). Insulin sensitivity was stable
inCBTandHE (ΔWBISI: .1 vs. .3) anddid not differ between groups (P= .63). However, among girls
with greater (moderate) baseline depressive symptoms (N= 78), those in CBT developed lower 2-
hr insulin than those in HE (Δ-16 vs. 16 𝜇IU/mL, P < .05). Additional metabolic benefits of CBT
were seen for this subgroup in post hoc analyses of posttreatment to 1-year change.
Conclusions: Adolescent females at risk for T2D decreased depressive symptoms and stabilized
insulin sensitivity 1 year following brief CBT or HE. Further studies are required to determine if
adolescents withmoderate depression showmetabolic benefits after CBT.
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1 INTRODUCTION
There is mounting attention to the role of depressive symptoms in
type 2 diabetes (T2D) risk and management (Thombs, 2014). Elevated
depressive symptoms in adults with T2D are associated with future
risk for poorer glycemic control, greater cognitive decline, and ear-
lier mortality (Semenkovich, Brown, Svrakic, & Lustman, 2015). Ran-
domized trials intervening on depression, either via behavioral or
pharmacological approaches, in adults with T2D demonstrate remis-
sion in major depressive disorder (MDD) and depressive symptoms,
but varied effects on glycemic control (Baumeister, Hutter, & Bengel,
2014).
Most studies of depression and T2D have involved adults, but
adolescence may be a preferable age for intervention. Depressive
symptoms increase during adolescence, primarily in girls (Hankin
et al., 1998), as does puberty-related insulin resistance, which influ-
ences future progression to T2D (Goran, Shaibi, Weigensberg, Davis,
& Cruz, 2006). Consistent with adult data (Yu, Zhang, Lu, & Fang,
2015), adolescent depressive symptoms correlate with poorer insulin
sensitivity, independent of body composition, and predict worsen-
ing insulin sensitivity and T2D onset over time, irrespective of body
mass index (BMI, kg/m2) or BMI gain (Shomaker & Goodman, 2015;
Shomaker et al., 2010, 2011; Suglia, Demmer, Wahi, Keyes, & Koenen,
2016).
Therefore, we hypothesized that decreasing depressive symptoms
during adolescence would prevent deterioration of insulin sensitiv-
ity in adolescents at risk for T2D. We conducted a randomized
controlled trial (Shomaker et al., 2016) to determine if a 6-session
weekly cognitive behavioral therapy (CBT) intervention designed to
decrease depressive symptoms would prevent worsening of insulin
sensitivity better than a health education (HE) standard-of-care con-
trol program among adolescent females at risk for T2D who also had
symptoms of depression. A preliminary report of the immediate 6-
week postintervention results showed that adolescents in both groups
decreased depressive symptoms (Shomaker et al., 2016). Across
groups, decreases in depressive symptoms were associated with
improvements in insulin sensitivity. Among adolescents who had mod-
erate (vs.mild) depressive symptoms,CBTproduced greater decreases
in depressive symptoms than HE. Insulin sensitivity remained stable
in all participants during this short-term interval. In the current paper,
we report changes in the primary efficacy outcome of insulin sensitiv-
ity over 1 year of follow-up. Adolescence is a dynamic period of the
lifespan marked by major changes in social, psychological, neural, and
biological domains (Steinberg, 2014). Previous longitudinal studies of
this age group illustrate that depressive symptoms exert an effect on
insulin resistance over the long-term (e.g., up to 5 years later), likely
through a cascade of effects on stress-related behavior and physi-
ology (Shomaker et al., 2011). In previous intervention studies, the
impact of decreasing psychological symptoms on physical growth and
endocrine outcomes frequently manifests to an increasingly greater
extent as development unfolds over a longer term follow-up interval,
such as 1–3 years (vs. directly after treatment; Tanofsky-Kraff et al.,
2017). We, therefore, anticipated that there would be more apparent
metabolic benefits of CBT, compared to HE, over the longer 1-year
follow-up.
Meta-analyses have found that baseline level of depressive symp-
toms is a potent moderator of the immediate and longer-term effects
of depression prevention programs (Stice, Shaw, Bohon, Marti, &
Rohde, 2009). Therefore, we hypothesized that degree of depressive
symptoms would moderate the treatment effect on insulin sensitivity,
with adolescents who were more depressed at baseline demonstrat-
ing greater 1-year metabolic benefits from CBT than those with mild
symptoms.
2 MATERIALS AND METHODS
2.1 Participants
One-hundred nineteen 12–17 years females were recruited for a T2D
prevention trial (ClinicalTrials.gov ID NCT01425905) through mail-
ings to area families, physician referrals, and posting of flyers. Partic-
ipants had overweight or obesity (BMI ≥ 85th percentile) and a fam-
ily history of T2D, prediabetes, or gestational diabetes in at least one
first- or second-degree relative. Adolescents were required to have
mild-to-moderate symptoms of depression, indicated by a total score
≥16 on the 20-item Center for Epidemiologic Studies—Depression
Scale (CES-D; Radloff, 1977), be in good general health, and have the
ability to speakandunderstandEnglish. Exclusion criteriawere current
psychiatric symptoms that necessitated treatment (e.g., MDD), major
medical problem (e.g., T2D: fasting glucose >126 mg/dL or 2-hr glu-
cose >200 mg/dL); medication use affecting insulin, weight, or mood
(e.g., anti-depressants); current involvement in structured weight loss
or psychotherapy; and pregnancy. Informed consent and assent were
obtained in writing from parents and adolescents, respectively, after
the procedures were explained. The study was carried out in compli-
ance with the Code of Ethics of the World Medical Association and
standards established by the Institutional Review Board of the Eunice
Kennedy Shriver National Institute of Child Health and Human Devel-
opment, which approved all procedures. Adolescents were compen-
sated for participation; transportation costs were covered for youth
who could not otherwise participate.
2.2 Study design
A parallel group, randomized controlled trial was conducted to com-
pare the effects of a CBT group with a HE standard-of-care control
group (Shomaker et al., 2016). All components were carried out at
the NIH Clinical Center in Bethesda, Maryland. Eleven cohorts of ado-
lescents participated from September 2011–July 2014. After a base-
line assessment to determine eligibility, participants were randomized
to CBT or HE. Randomization, generated by an electronic program
with permuted blocks, was stratified by age and race/ethnicity. Groups
were run in parallel on weekdays after school, in separate clinics to
deter cross-contamination. Follow-ups were completed at posttreat-
ment and 1 year.
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2.3 Experimental groups
2.3.1 Cognitive behavioral therapy (CBT)
The CBT groupwas amanualized depression prevention program con-
sisting of 1-hr sessions, once per week for 6 weeks (Stice, Rohde, See-
ley, & Gau, 2008). On average, there were six adolescents in the CBT
group per cohort (range = 3–8). The program has efficacy for decreas-
ing adolescent depressive symptoms and reducing MDD onset, com-
pared to assessment-only and active controls, for up to 2 years (Rohde,
Stice, Shaw, & Briere, 2014; Stice et al., 2008; Stice, Rohde, Gau, &
Wade, 2010). Stronger effects are observed in adolescents with base-
linemoderate, compared tomild, depressive symptoms (Muller, Rohde,
Gau, & Stice, 2015).
Sessionswere interactive, activity-based, and includedmotivational
enhancement. Content included key CBT modules of psychoeduca-
tion about interconnectedness of feelings, thoughts, and behaviors,
self-monitoring, self-reinforcement, positive self-statements, cogni-
tive restructuring of negative thoughts, engagement in pleasant activ-
ities, and coping. Adolescents were assigned weekly homework to
apply concepts learned in the sessions to their daily lives. The group
was cofacilitated by one of six clinical psychologists and one of three
clinical psychology doctoral students. Facilitators alternated between
CBT and HE to control for possible therapist effects. Facilitators were
trained by a program developer (ES). All sessions were audio-recorded
so that therapists could receive ongoing, detailed weekly supervision
from the lead psychologist (LS). In addition, a noninvestigator program
expert reviewed 20% of randomly selected audio recordings and rated
them for session fidelity and leader competence using the rating scales
created by the developers of this program (Stice et al., 2008). With
regard to fidelity, median ratings of CBT sessions were 7.7 on a scale
ranging from1=none to10=perfect.With regard to therapist compe-
tence, median ratings of CBT sessions were 7.8 on a scale ranging from
1= poor to 10= superior. Therewas no crossoverwithHE identified in
the taped sessions (Shomaker et al., 2016).
2.3.2 Health education (HE)
The standard-of-care HE group was adapted from a didactic, middle,
and high school HE curriculum (“Hey-Durham”; Bravender, 2005). To
match CBT for time and attention, the HE groupmet for 1-hr sessions,
once per week for 6 weeks. On average, there were five adolescents
in the HE group per cohort (range = 3–9). The manualized curriculum
covered education about substance use, nutrition, exercise, body
image, domestic violence, conflict resolution, sun safety, and identify-
ing depression and signs of suicide. The depression and suicidemodule
focused on prevalence of these problems, their relation to other
health issues, and how to identify warning signs. No direct personal
counseling or advice was provided, other than in the event of a psychi-
atric crisis or suicidal ideation, in which case a treatment referral was
facilitated.
2.4 Demographic andmedical information
Parents reported adolescents’ age and race/ethnicity. A nurse prac-
titioner or endocrinologist conducted a medical history and physical.
Breast development was assessed by physical inspection and palpita-
tion, and maturation was assigned according to the five Tanner stages
(Marshall & Tanner, 1969).
2.5 Outcomemeasures
All measurements were collected at baseline, repeated at an immedi-
ate posttreatment assessment and 1 year later. Assessors were blind
to group assignment.
2.5.1 Anthropometrics
Participants in the fasted state removed shoes and outer clothing to be
weighed to the nearest 0.1 kg with a digital scale. Height was deter-
mined with a wall stadiometer from the average of three measure-
ments to the nearest millimeter. BMI (weight in kg/[height in m2]) and
BMIz were calculated by CDC 2000 standards (Ogden et al., 2002).
Total fat mass (kg) was derived from dual-energy X-ray absorptiom-
etry (iDXA, GEHealthcare, Madison,WI) at baseline and 1 year.
2.5.2 Depressive symptoms and psychological functioning
The total score of the 20-item CES-D was used to determine study
inclusion (≥16) and to provide a continuous measure of depres-
sive symptoms (Radloff, 1977). We categorized participants as those
with mild symptoms (total score = 16–20) and those with moder-
ate depressive symptoms (>20; Stockings et al., 2015). To determine
presence of MDD or another psychiatric disorder in the past year,
the Schedule for Affective Disorders and Schizophrenia for School-
Age Children (K-SADS; Kaufman et al., 1997) was administered to
adolescents by a trained interviewer. The K-SADS has adequate test–
retest reliability, internal consistency, and predictive validity in ado-
lescents (Nolen-Hoeksema, Stice, Wade, & Bohon, 2007), and in this
sample, demonstrated good inter-rater reliability forMDD (k=0.89 on
20% of interviews).
2.5.3 Oral glucose tolerance test
An oral glucose tolerance test (OGTT) was performed in the morning
following an overnight fast initiated at 10:00 pm the previous evening.
Participants received 1.75 g/kg of dextrose (maximum75 g). Bloodwas
sampled for serum insulin and plasma glucose at fasting and at 30, 60,
90, and 120 min after dextrose. Insulin and glucose were determined
using standardmethodsaspreviously reported (Shomaker et al., 2016).
Whole body insulin sensitivity index (WBISI) was calculated as 10,000
divided by the square root of the product of fasting glucose (mg/dL)
and fasting insulin (mIU/mL) times the product of mean glucose0–120
(mg/dL) and mean insulin0–120 (mIU/mL). WBISI has been validated
against clamp-derived measures (Yeckel et al., 2004). Higher WBISI
values represent better insulin sensitivity and lower values represent
poorer insulin sensitivity. Change inWBISI over 1 yearwas the primary
outcome. As secondarymeasures, we evaluated fasting insulin and glu-
cose, 2-hr insulin and glucose, and homeostasis model assessment of
insulin resistance (HOMA-IR). Higher HOMA-IR values reflect worse
insulin resistance and lower values reflect little to no insulin resistance.
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2.6 Statistical methods
A planned sample of 58 per group, allowing for 30% attrition,
provided 80% power using a two-sided 𝛼 level of .05 to detect a
moderate effect (SD = 0.54) in the primary 1-year outcome of insulin
sensitivity. Analyses were conducted with SPSS 23 (IBM, 2015)
and SAS 9.3 (SAS Institute Incorporated, 2011). The intent-to-treat
sample consisted of participants who were randomized, regardless
of whether they withdrew or were excluded after randomization.
A priori, individuals who developed an exclusion criterion, including
pregnancy,medication use (e.g., stimulants, anti-depressants, or insulin
sensitizers), or regular psychotherapy, were withdrawn during the
follow-up phase, so that any observed effects were not confounded
by these variables. The intent-to-treat sample included the data
from these participants to the point at which they were withdrawn,
and missing data were imputed. Binary logistic regression was used
to evaluate baseline predictors of 1-year attrition. ANCOVAs were
conducted to characterize 1-year change from baseline in depressive
symptoms, BMI (kg/m2), and fat mass (kg) by group. In these models,
we adjusted for baseline depressive symptoms, BMI or fat mass, and
time to follow-up, baseline age, pubertal status, degree of diabetes
family history, race/ethnicity, and group facilitator. We also accounted
for baseline BMIz inmodels predicting change in depressive symptoms
and fat mass. Parallel ANCOVAs were conducted with the primary
outcome of 1-year insulin sensitivity change as the dependent variable
and group as the independent variable. Covariates included baseline
insulin sensitivity, baseline fat mass, baseline to posttreatment fat
mass change, time to follow-up, baseline BMIz, age, pubertal status,
diabetes family history, race/ethnicity, and facilitator. Parallel ANCO-
VAs evaluated secondary outcomes of changes in HOMA-IR, fasting,
and 2-hr insulin and glucose. Multiple imputation using Monte Carlo
Markov chain method in SAS PROC MI with 20 imputed datasets
was used to handle missing data. We also conducted analyses with
complete data using listwise deletion. Analyses were conducted
for the entire sample and for the subset with baseline moderate
depressive symptoms, because this subset had greater posttreatment
decreases directly after CBT versus HE (Shomaker et al., 2016).
As post hoc analyses, we evaluated metabolic change during the
follow-up period, by predicting changes from posttreatment to 1-year.
This approach addresses metabolic improvement/deterioration dur-
ing the maintenance phase following the intervention (Eakin et al.,
2014).
3 RESULTS
In the total sample (Table 1), baseline BMI and BMIz were lower in
CBT than HE (P < .05), with no other differences (Ps > 0.10). Sixty-
six percent (n = 78) of the sample had moderate baseline depressive
symptoms. Similar percentages with moderate depressive symptoms
were randomized to CBT (68.9%) and HE (62.1%; P = .44). Overall,
adolescents with moderate depressive symptoms were older (15.2 ±
1.5 years vs. 14.6 ± 1.6 years, P = .03) than those with milder symp-
toms, but did not differ in other characteristics. Among the subsetwith
baseline moderate depressive symptoms, there were no differences
between those in CBT versus HE (Ps> 0.06).
Study flow is displayed in Figure 1. Program attendancewas high; in
CBT, 80% (n = 49) and in HE, 79% (n = 46) of adolescents attended at
least five (80%) of six sessions (P = .89). Seventy-two percent in CBT
(n= 44) and 74% (n= 43) in HE completed a 1-year follow-up (P= .81).
Dropouts were more likely to have been in early/mid-puberty (Tanner
2–3) than late puberty (Tanner 4–5) at baseline (OR = 8.49, 95% CI:
2.07–34.74, P= .003), with no other differences (Ps> .21).
3.1 Depressive symptoms
3.1.1 Full sample
At 1-year, few adolescents developedMDD in either group (CBT: 3.3%,
n= 2 vs. HE: 1.7%, n= 1, P= .59). Another 11 adolescents (CBT: 8.2%, n
=5vs.HE:10.3%,n=6,P= .69)werewithdrawnbecause they starteda
psychotropic medication (e.g., antidepressant) or initiated regular psy-
chotherapy. Adjusting for covariates, adolescents in CBT and HE both
had significant decreases (Ps < 0.001) in depressive symptoms from
baseline to 1 year (ΔMean± SE, CBT:Δ-12.0± 1.2 vs. HE:Δ-12.4± 1.2,
P= .81). Figure 2Adepicts the course of depressive symptoms over the
study.
3.1.2 Sample subset
Among adolescents with baseline moderate depressive symptoms, all
participants decreased depressive symptoms from baseline to 1 year
(P< .001), with no group difference (CBT:Δ-14.0± 1.6 vs. HE:Δ-14.8±
1.6, P= .72; Figure 2B).
3.2 BMI and adiposity
3.2.1 Full sample
Accounting for covariates, BMI change from baseline to 1 year did not
differ between groups (CBT:Δ0.7± 0.3 kg/m2 vs. HE:Δ0.9± 0.3 kg/m2,
P = .61). There was no group effect on body fat (CBT:Δ1.9 ± 0.6 kg vs.
HE:Δ2.1± 0.6 kg, P= .83).
3.2.2 Sample subset
Among adolescents with baseline moderate depressive symptoms,
therewas no group effect on baseline to 1-year BMI change (CBT:Δ0.6
± 0.4 vs. HE:Δ0.8 ± 0.4, P = .78). Likewise, there was no difference in
1-year body fat change (CBT:Δ1.8± 0.7 vs. HE:Δ1.7± 0.7, P= .90).
3.3 Insulin sensitivity and other indices
3.3.1 Full sample
One teen (HE) developed criteria for T2D and was referred to her
physician for follow-up. Table 2 displays results for baseline to 1-year
change in insulin sensitivity and other indices. There was no group
effect on insulin sensitivity (P = .54) or any secondary index (Ps > .18).
At 1 year, insulin sensitivity showed within-group stability in CBT and
HE (Figure 2C), as did all other metabolic indicators (Ps> 0.12).
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TABLE 1 Descriptive Baseline Information by Group Assignment, for the Total Sample and for Adolescent Females with Moderate Depressive
Symptoms
Total Sample Moderate Depressive Symptomsa
Characteristic CBT HE CBT HE
N 61 58 42 36
Age, yearsb 15.0± 1.6 15.1± 1.6 15.2± 1.5 15.3± 1.5
Race, n (%)
Non-Hispanic black 39 (63.9) 35 (60.3) 27 (64.3) 23 (63.9)
Non-Hispanic white 8 (13.1) 11 (19.0) 7 (16.7) 7 (19.4)
Hispanic 7 (11.5) 5 (10.3) 5 (11.9) 2 (5.6)
Other 7 (11.5) 6 (10.3) 3 (7.1) 4 (11.1)
Tanner breast stage, n (%)
1–2 2 (3.3) 2 (3.4) 2 (4.8) 1 (2.8)
3 7 (11.4) 4 (6.9) 3 (7.2) 2 (5.6)
4 7 (11.5) 13 (22.4) 5 (11.9) 6 (16.7)
5 45 (73.8) 39 (67.2) 32 (76.2) 27 (75.0)
BMI (kg/m2)b 31.7± 6.1 34.4± 7.3 32.2± 6.5 34.7± 6.5
BMIzb 1.9± 0.4 2.1± 0.5 1.9± 0.5 2.1± 0.4
Percentage of body fatb 40.8± 5.4 42.5± 6.0 40.7± 5.5 42.6± 5.9
Depressive symptomsb 25.3± 7.3 24.5± 7.5 28.7± 6.2 28.4± 7.1
Hba1c (%)b 5.3± 0.4 5.3± 0.3 5.4± 0.3 5.4± 0.3
WBISIb 2.7± 1.7 2.3± 1.4 2.7± 1.8 2.5± 1.4
HOMA-IRb 5.3± 4.3 7.1± 7.4 5.5± 4.8 6.2± 5.2
Fasting insulin (𝜇IU/mL)b 23.9± 18.6 30.6± 27.5 24.9± 20.9 27.4± 21.1
2-hr insulin (𝜇IU/mL)b 147.1± 131.8 131.0± 129.7 131.3± 127.6 137.4± 123.8
Fasting glucose (mg/dL)b 88.6± 6.7 89.7± 7.6 88.1± 7.0 89.6± 6.7
2-hr glucose (mg/dL)b 102.8± 21.0 105.9± 22.4 101.3± 19.7 108.0± 23.3
aModerate depressive symptoms refer to a Center for Epidemiologic Studies–Depression Scale (CES-D) total score>20.
bMean (SD). CBT, cognitive behavioral group; HE, health education group; WBISI, whole body insulin sensitivity index, with higher values reflecting better
insulin sensitivity and lower values poorer insulin sensitivity;HOMA-IR, homeostasismodel assessment of insulin resistance,with higher values representing
greater insulin resistance and lower values little to no insulin resistance; Hba1c, glycated hemoglobin.
3.3.2 Subset withmoderate depression
In adolescents with baseline moderate depressive symptoms, there
was no groupdifference in insulin sensitivity (P= .93; Figure2D). There
was a group effect on 2-hr insulin. Participants in CBT had a greater
decrease in 2-hr insulin from baseline to 1 year than HE (group effect
Δ-32.5±16.3 𝜇IU/mL, P = .048, Cohen’s d = 0.51). The same pattern
was observed in analyses with completer data (Δ-40.0 ± 16.3 𝜇IU/mL,
P= .019, Cohen’s d= 0.64).
3.4 Post-hoc analyses of metabolic maintenance
3.4.1 Full sample
There were no effects of condition on insulin sensitivity or secondary
outcomes (Ps> .05).
3.4.2 Subset withmoderate depression
In adolescents with baseline moderate depressive symptoms, the
group effect on insulin sensitivity did not reach significance (group
effect Δ0.56 ± 0.33, P = .09, Cohen’s d = 0.35; Table 3). In analyses
with completer data, there was a group effect on insulin sensitivity
(Δ0.80 ± 0.31, P = .02, Cohen’s d = 0.56). Adolescents in CBT showed
posttreatment to 1-year stability in insulin sensitivity (ΔWBISI= 0.08;
95% CI: −0.38 to 0.54), whereas those in HE showed deterioration
(ΔWBISI=−0.72; 95%CI:−1.31 to−0.13).
For secondaryoutcomes, therewasagroupeffect onposttreatment
to 1-year change in fasting insulin. Adolescents in CBT showed a pat-
tern toward decreased fasting insulin, and those in HE had no change
(group effect Δ-6.89 ± 3.49 𝜇IU/mL, P = .048, Cohen’s d = 0.43). This
effect becamemarginal (P= .09) in completer analyses. There also was
a group effect on posttreatment to 1-year change in 2-hr insulin. CBT
had no change, whereas HE showed increases in 2-hr insulin (group
effectΔ-50.6± 21.8 𝜇IU/mL, P= .02, Cohen’s d= 0.61). This effectwas
more pronounced in completer analyses (group effectΔ-67.43±22.70
𝜇IU/mL, P= .006, Cohen’s d= 0.94).
4 DISCUSSION
The objective of this randomized controlled trial was to test if deterio-
ration in insulin sensitivity could be prevented by directly intervening
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F IGURE 1 Study flow from initial assessment to 1-year follow-up; 6-week follow-up, immediate posttreatment results have been published else-
where (Shomaker et al., 2016)
with depressive symptoms in adolescent girls at risk for T2D with
mild-to-moderate depressive symptoms. Following participation
in either a 6-week CBT depression prevention group or a 6-week
HE control group, adolescents in both conditions had decreases in
depressive symptoms and stable insulin sensitivity 1 year later, with
no differences between groups. In a subset analysis of those with
greater (i.e., moderate) depressive symptoms at baseline, adolescents
randomized to CBT had greater declines in 2-hr insulin at 1 year than
did adolescents randomized to HE.
Among those with moderate baseline depressive symptoms, CBT
participants had greater acute decreases in depressive symptoms than
HE (Shomaker et al., 2016). Yet, there was no difference between CBT
and HE in 1-year depressive symptoms, regardless of initial symp-
tom severity. CBT and HE were matched for time, intensity, deliv-
ery mode, and facilitator expertise. CBT provides psychoeducation
on depression, teaches tools to restructure negative thoughts, and
encourages behavioral activation; yet, both conditions were delivered
in a group format with same-sex peers, under the supervision of a
psychologist, lending themselves to some degree of nonspecific social
support in both contexts. Consistent with this explanation, past
investigations of CBT depression prevention were less robust for
decreasing depressive symptoms when compared to an active con-
trol such as a supportive–expressive group over a 6-month or longer
follow-up (Rohdeet al., 2014; Stice et al., 2008, 2010). A similar pattern
of more rapid change, with equivocal longer term outcomes in depres-
sive symptoms, has been observed with other therapeutic modalities
for depression prevention (e.g., interpersonal psychotherapy) when
compared to an active control (Young, Mufson, & Gallop, 2010). With-
out an assessment only condition, it is not possible to determine
whether participation in CBT and HE caused the decreases that were
observed in depressive symptoms at 1 year, or whether the changes
reflect regression to the mean. In addition, we may not have had ade-
quate power to detect an effect on 1-year change in depressive symp-
toms among the subset of more depressed adolescents.
Insulin sensitivity was stable following CBT and HE. This pattern
is notable given that deterioration in insulin sensitivity would be
expected in adolescents at risk for T2D (Goran et al., 2006). We can-
not rule out that overall stabilization of insulin sensitivity occurred
because of other variables. For instance, it is possible that completion
of pubertal development could explain the stabilization observed in
insulin sensitivity (Moran et al., 1999), despite the gains in adiposity
observed in the cohort.
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F IGURE 2 Time course over the study of adolescent depressive symptoms, as assessed on the Center for Epidemiologic Studies-Depression
Scale (CES-D), and of whole body insulin sensitivity (WBISI), with greater values reflecting better insulin sensitivity and lower values reflecting
poorer insulin sensitivity. Panels A and C characterize the total sample; Panels B and D describe the subset with baseline moderate depressive
symptoms (CES-D> 20) only. Values displayed are derived frommultiply imputed data and are adjusted for covariates
Because of the heterogeneity in depressive symptoms in this
sample, and evidence of greater decreases in symptoms in CBT versus
HE at posttest for those with initially higher baseline depressive
symptoms (Shomaker et al., 2016), we evaluated the group effect on
metabolic outcomes in the sample subset with baseline moderate
depressive symptoms. Adolescents with moderate depressive symp-
toms at baseline had lower 2-hr insulin at 1 year in CBT compared
to HE. This finding was consistent in multiply imputed and complete
data, and represented amedium effect size.Whenwe explored, in post
hoc analyses, changes in metabolic outcomes over the maintenance
interval, adolescents with baseline moderate depressive symptoms
in CBT had better fasting and 2-hr insulin from posttreatment to
1 year than HE. Although fasting and 2-hr insulin were secondary
metabolic outcomes, these indices have been identified as two of the
most salient, early markers of T2D and cardiovascular disease risk in
youth (Libman et al., 2010). Using complete data, adolescents with
baseline moderate depression symptoms in CBT had stable insulin
sensitivity, whereas those in HE showed deterioration in insulin sen-
sitivity during the follow-up interval. These subgroup analyses require
replication with an adequately powered sample of adolescents with
moderate depressive symptoms. These preliminary findings raise the
possibility that a stand-alone treatment for mental health could have a
sustained impact on metabolic trajectories, but additional studies are
required.
The explanatory mechanisms by which CBT potentially led to
improvements in 1-year insulin outcomes in adolescents with moder-
ate depressive symptoms remain unclear, but are of great interest. Of
note, we accounted for initial adiposity and change in adiposity, indi-
cating that the observed effects were not explained merely by the
relationships of depressive symptoms and insulin to adiposity. If
addressing depressive symptoms lessens the risk of developing T2D,
even without inducing weight loss, this would have significant impli-
cations for preventative medicine. Theoretically, stress-related behav-
iors and physiology may underlie the direct connection between
depression and insulin resistance. Decreasing depressive symptoms
acutely may lead, over time, to subsequent changes in stress mech-
anisms, which in turn ameliorate insulin resistance as adolescents
develop (Shomaker et al., 2016). Potentially contributing stress-
related behavioral factors, including disinhibited eating (Tanofsky-
Kraff et al., 2012), sleep disturbance (Depner, Stothard, & Wright,
2014), infrequent moderate-to-vigorous physical activity, and habit-
ual sedentary time (Berman, Weigensberg, & Spruijt-Metz, 2012;
Poitras et al., 2016), require exploration in future studies. Likewise,
stress-related physiological factors that have been associated with
depressive symptoms and diabetes risk, such as hypercortisolism and
a proinflammatory imbalance (Adam et al., 2010), may be explana-
tory and should be evaluated in future studies as possible mediating
mechanisms.
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Strengths of this study include the randomized controlled trial
design, use of an active control, reliable and validated measures, and
focus on a novel, targeted approach to prevention of T2D in adoles-
cents at risk for this chronic disease. Power was adequate for the full
sample and 1-year retention was good. Yet, group effects were only
observed in a subset with baseline moderate depressive symptoms,
and as a consequence, these analyses were not adequately powered.
The total number of analyses increases odds of chance effects, despite
the a priori nature of the aims. Generalizability is limited by the specific
selection criteria, including adolescent girls with overweight/obesity,
a family diabetes history, andmild-to-moderate depressive symptoms.
Most of the sample was non-Hispanic Black/African American, reflect-
ing the demographic of the study’s geographic area. Caution should be
exercised in generalizing thefindings tomales or other race/ethnicities.
The study design involved withdrawal during the follow-up of sub-
jects who developed an exclusion criterion, including the initiation of
medication or regular therapy. Although this strategy minimized the
confounding influence of these factors on treatment outcomes and
missing data were handled with multiple imputation, it contributed to
a more incomplete follow-up and could have led to biased estimates
(in either direction). Despite the high insulin resistance of this cohort,
only one adolescent converted to T2D over 1 year, suggesting that an
even longer term follow-up to capture possible differences in deteri-
oration of insulin sensitivity and in the emergence, or prevention, of
youth-onset T2Dwould be valuable.
The dramatic increase in prevalence of youth-onset T2D, particu-
larly in girls and in disadvantaged racial/ethnic groups (Dabelea et al.,
2014), calls for novel approaches to T2D prevention. If a relatively
brief, 6-week/6-hr psychosocial intervention impacts diabetes risk, it
would offer the potential of a cost-effective, targeted, preventative
approach in high-risk youth. Additional studies are essential to test
whether brief CBT programs can improve insulin action and secretion
in adolescents at high risk for depression and diabetes in the long term,
and to determine themechanisms of action.
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